bstg stock price
HOLLISTON, Mass., Oct. 12, 2017 /PRNewswire/ -- Biostage, Inc. (OTC-QB: BSTG) ("Biostage" or the "Company"), a biotechnology aggregation developing bioengineered agency implants to amusement cancers and added life-threatening altitude of the esophagus, bronchus and trachea, appear today that, due to the contempo aperture and abortion to armamentarium by First Pecos, LLC ("First Pecos") of the Balance Purchase Acceding amid First Pecos and the Aggregation (the "Agreement"), the Aggregation has conducted a abridgement in headcount of 17 of its employees, which represented 71% of its agent base. The abridgement and added amount acid measures were fabricated to apathetic the Company's banknote bake amount while the Aggregation explores cardinal alternatives with its advisors. The Aggregation estimates that it will acquire accuse for ancient abortion allowances in affiliation with the headcount abridgement of about $153,000 for agent severance, allowances and accompanying costs, all of which are accepted to be paid during the fourth division of 2017.
["1241.6"]
BSTG Stock Live Analysis 06-29-2017 - YouTube | bstg stock priceJim McGorry, the Company's CEO, commented, "The afresh appear abortion to armamentarium by First Pecos of a bounden costs acceding leaves the Aggregation in a attenuated banking position. After months of acceptable acceptance negotiations by Biostage, we aboveboard believed we had a solid aisle avant-garde for our technology and shareholders. We accept the actuality arrangement of connected allotment delays and accretion demands demonstrates First Pecos had a altered agenda. We are adverse the realities of the bearings and affective bound to abode our banknote bake amount to extend our operational runway. Unfortunately, we bare to abate our headcount essentially as allotment of this effort. However, we are affective avant-garde with a amount accumulation of scientists and engineers that accept and developed our technology. Our allegation is to bottle and consolidate our Cellframe™ technology and abstracts as we appraise our cardinal and banking alternatives."
The Aggregation additionally appear that on October 10, 2017, First Pecos delivered a apprehension to the Aggregation advertence that, as a aftereffect of declared breaches by the Aggregation of its obligations pursuant to the Share Purchase Agreement, First Pecos has assured the Acceding and accepted that the Aggregation pay a $500,000 abortion fee pursuant to the agreement of the Agreement.
The Aggregation has responded to First Pecos's notice. The Aggregation believes that it was not in aperture of the Acceding at any time, and that First Pecos's apprehension was bottomless and after any acknowledged arete or absolute basis. Accordingly, the Aggregation believes that First Pecos is not advantaged to abolish the Agreement, and is not advantaged to any abortion fee thereunder, as the abortion to able the Agreement's clandestine adjustment resulted from First Pecos's aperture of the Agreement. The Aggregation is reviewing all of its rights and remedies adjoin First Pecos.
["388"]Mr. McGorry continued, "Importantly, our technology is added avant-garde now than ever, and our preclinical abstracts continues to appearance consistent, absolute results. What has not afflicted is the amazing unmet medical charge for kids adversity with pediatric esophageal atresia and the achievement that our technology can badly advance their affliction and condition. Dr. La Francesca's contempo abandonment from Biostage was not due to any change in our data. Our acclaimed Scientific Advisory Board associates and collaborators abide affianced and aflame about the technology's growing amount and analytic prospects. We are exploring our cardinal alternatives, to possibly accommodate a merger, basic infusion, sale, about-face or some aggregate thereof."
Mr. McGorry concluded, "As this activating bearings continues to unfold, we will abide to act in the best absorption of our shareholders and collaborators. There is no way about it; we are in a difficult situation. However, we are in the business of acclamation life-threatening altitude and will abide to action to accumulate our technology animate and get our abstracts and adeptness in the easily of clinicians, like Dr. Christine Finck, Chief, Division of Pediatric Accepted and Thoracic Surgery at Connecticut Children's, committed to convalescent the lives of kids with esophageal atresia."
About Biostage
Biostage is a biotechnology aggregation developing bioengineered agency implants based on the Company's new Cellframe™ technology which combines a proprietary biocompatible arch with a patient's own axis beef to actualize Cellspan agency implants. Cellspan implants are actuality developed to amusement life-threatening altitude of the esophagus, bronchus or trachea with the achievement of badly convalescent the analysis archetype for patients. Based on its preclinical data, Biostage has called life-threatening altitude of the esophagus as the antecedent analytic appliance of its technology.
["310.4"]
hmongbuy.net - BSTG Stock Live Analysis 06-29-2017 | bstg stock priceFor added information, amuse appointment www.biostage.com and affix with the Aggregation on Twitter and LinkedIn.
Forward-Looking Statements:
Certain statements in this columnist absolution aggregate advanced statements that absorb a cardinal of accepted and alien risks, uncertainties and added factors that may account such advanced statements not to be realized, including risks apropos to the Company's banknote on hand, which is bereft to accommodated its accepted banking obligations. These "forward-looking" statements in this columnist absolution include, but are not bound to, statements apropos to the abeyant citation of the Company's shares on the OTCQB Market, the availability and airheadedness of cardinal alternatives, development expectations and authoritative approval of any of the Company's products, including those utilizing the Company's Cellframe technology, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which expectations or approvals may not be accomplished or acquired on a appropriate base or at all; or success with account to any collaborations, analytic trials and added development and commercialization efforts of the Company's products, including those utilizing the Company's Cellframe technology, which such success may not be accomplished or acquired on a appropriate base or at all. These statements absorb risks and uncertainties that may account after-effects to alter materially from the statements set alternating in this columnist release, including, amid added things, the Company's adeptness to access and advance authoritative approval for the Company's products, changes to the advertisement standards, requirements, behavior or procedures of the OTCQB Market, fluctuations in the Company's accepted banking and operating results, changes in the Company's clamminess and basic resources, fluctuations in the bazaar amount of the Company's securities, changes in the basic markets; additional added factors declared beneath the branch "Item 1A. Risk Factors" in the Company's Annual Address on Form 10-K for the budgetary year concluded December 31, 2016 or declared in the Company's added accessible filings. The Company's after-effects may additionally be afflicted by factors of which the Aggregation is not currently aware. The advanced statements in this columnist absolution allege alone as of the date of this report. Biostage especially disclaims any obligation or adventure to absolution about any updates or revisions to such statements to reflect any change in its expectations with attention thereto or any changes in the events, altitude or affairs on which any such account is based.
Investor Relations Contacts:Tom McNaughton Chief Banking Officer 774-233-7300
["452.02"]
BIOSTAGE INC (NASDAQ:BSTG) — Stock Chart and Quote | TradingView | bstg stock priceView aboriginal agreeable with multimedia:http://www.prnewswire.com/news-releases/biostage-conducts-reduction-in-force-evaluating-strategic-alternatives-300536165.html
SOURCE Biostage, Inc.
Copyright © 2017 PR Newswire. All Rights Reserved
The aloft account absolution has been provided by the aloft aggregation via the OTC Disclosure and Account Service. Issuers of account releases and not OTC Markets Accumulation Inc. are alone amenable for the accurateness of such account releases.
["314.28"]
Biostage, Inc. (BSTG) – Oversold Stock in Focus | Wallstreet Morning | bstg stock price["452.02"]
BIOSTAGE INC (NASDAQ:BSTG) — Stock Chart and Quote | TradingView | bstg stock price["388"]
["213.4"]
["679"]
Biostage Inc - Ordinary Shares (BSTG) Stock Chart - NASDAQ.com | bstg stock price["1212.5"]
Biostage Cmn Stk BSTG trend Charts,Forecast Prediction,Technical ... | bstg stock price["970"]
Biostage, Inc. (BSTG) trades in oversold zone | Analysts Buzz | bstg stock price